Recent studies on retatruded, a dual activator for glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, demonstrate significant outcomes in managing excess body fat and type 2 glucose intolerance. Initial information from clinical experiments reveal substantial decreases in body mass and enhanced glucose levels. Further researc